Lymphoma study: TLN-121 vs Zeprumetostat
Official title TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
ClinicalTrials.gov ID: NCT07082803
What this study is testing
What is TLN-121?
TLN-121 is an investigational medicine, being studied as a potential treatment for lymphoma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether TLN-121 is safe. It also looks at early anti‑tumor activity in people with relapsed or refractory Non‑Hodgkin lymphoma.
- Who it's for
- You may be able to join if you have relapsed or refractory Non‑Hodgkin lymphoma.
- What's involved
- You would receive TLN-121 alone or together with other lymphoma medicines. You will have clinic visits for safety checks and blood tests.
- Time commitment
- The study lasts several months with regular visits during treatment.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Disease Characteristics
- Participant must have measurable disease at study entry
- Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBLC), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade...
- FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.
- Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).
You likely can't join if
- Participants must not have current central nervous system (CNS) involvement.
- Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days...
- Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.
- Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
- Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence...
- Pregnant or lactating.
See the full eligibility criteria
- Disease Characteristics
- Participant must have measurable disease at study entry
- Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBLC), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade 3b, transformed lymphoma from FL, or High-Grade B-Cell lymphoma (HGBCL)...
- FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.
- Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).
- Nodal Tfh cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.
- Nodal Tfh cell lymphoma, NOS; Follicular helper T-cell lymphoma, NOS.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must not have current central nervous system (CNS) involvement. Participants with past history of CNS involvement of lymphoma must have had CNS disease fully treated with no evidence of recurrence within 12...
- Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days prior to the start of the study.
- Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.
- Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
- Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable...
- Pregnant or lactating.
- Conditions that could affect drug absorption.
The study team makes the final eligibility decision.
Where it is enrolling
- Palo Alto, California, United States
- Grand Rapids, Michigan, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Philadelphia, Pennsylvania, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Macquarie Park, New South Wales, Australia
- Woolloongabba, Queensland, Australia
- Malvern, Victoria, Australia
- Melbourne, Victoria, Australia
- Perth, Western Australia, Australia
- Vancouver, British Columbia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Palo Alto, California, United States; Grand Rapids, Michigan, United States; St Louis, Missouri, United States; New York, New York, United States; Philadelphia, Pennsylvania, United States; Nashville, Tennessee, United States and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.